Search Within

Debra Marion Sarasohn

  1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (9)
  2. Meeting Abstract (1)
Groups
  1. Body Imaging Service (10)
  2. Department of Medicine (10)
  3. GDMT, Medicine (10)
  4. Gynecologic Medicine Service (10)
  5. Gynecology Disease Management Team (10)
  6. Radiology, Department of (10)

More Groups

People
  1. Carol Aghajanian (7)
  2. Roisin O'Cearbhaill (6)
  3. Alexia Iasonos (5)
  4. Dmitriy Zamarin (5)
  5. Jason Konner (5)
  6. William Tew (5)

More People

Years
  1. 2024 (1)
  2. 2023 (4)
  3. 2020 (1)
  4. 2018 (1)
  5. 2016 (1)
  6. 2014 (1)

More Years

Publications
  1. Gynecologic Oncology (4)
  2. Journal of Clinical Oncology (2)
  3. American Journal of Roentgenology (1)
  4. Annals of Surgical Oncology (1)
  5. Cancers (1)
  6. Gynecologic Oncology Reports (1)
Publishers
  1. Elsevier Inc. (4)
  2. American Society of Clinical Oncology (2)
  3. American Roentgen Ray Society (1)
  4. Elsevier B.V. (1)
  5. MDPI (1)
  6. Springer (1)

Results (10)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)
    Journal Article

    Lumish, M.; Chui, M. H.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Cohen, S.; Friedman, C.; Grisham, R.; Konner, J.; Kyi, C.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Synoptic reporting for pretreatment CT examination in patients with advanced ovarian cancer: Impact on documentation of disease sites and physician satisfaction
    Journal Article

    Andrieu, P. C.; Nikolovski, I.; Juluru, K.; Sadowski, E.; Gangai, N.; Zheng, J.; Capanu, M.; Praiss, A. M.; Nougaret, S.; Shinagare, A. B.; more...
    American Journal of Roentgenology (2023)

    Fulltext@MSK | Save
  • Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
    Journal Article

    Lam, C.; Sarasohn, D.; Weigelt, B.; Zamarin, D.
    Gynecologic Oncology Reports (2023)

    Fulltext@MSK | Save
  • Phase I study of a multivalent WT1 peptide vaccine (galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission
    Journal Article

    Manning-Geist, B. L.; Gnjatic, S.; Aghajanian, C.; Konner, J.; Kim, S. H.; Sarasohn, D.; Soldan, K.; Tew, W. P.; Sarlis, N. J.; Zamarin, D.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Journal Article

    Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Boucicaut, N. N.; Henson, M.; Iasonos, A.; Zhou, Q.; Sarasohn, D. M.; Gallagher, J.; Kravetz, S.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission
    Meeting Abstract

    O'Cearbhaill, R. E.; Gnjatic, S.; Aghajanian, C.; Iasonos, A.; Konner, J. A.; Losada, N.; Sarasohn, D.; Rasalan, T.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Is it time to centralize ovarian cancer care in the United States?
    Journal Article

    Cowan, R. A.; O’Cearbhaill, R. E.; Gardner, G. J.; Levine, D. A.; Long Roche, K.; Sonoda, Y.; Zivanovic, O.; Tew, W. P.; Sala, E.; Lakhman, Y.; more...
    Annals of Surgical Oncology (2016)

    Fulltext@MSK | Save
  • A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer
    Journal Article

    Suidan, R. S.; Ramirez, P. T.; Sarasohn, D. M.; Teitcher, J. B.; Mironov, S.; Iyer, R. B.; Zhou, Q.; Iasonos, A.; Paul, H.; Hosaka, M.; more...
    Gynecologic Oncology (2014)

    Fulltext@MSK | Save
  • Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less
    Journal Article

    Chi, D. S.; Ramirez, P. T.; Teitcher, J. B.; Mironov, S.; Sarasohn, D. M.; Iyer, R. B.; Eisenhauer, E. L.; Abu-Rustum, N. R.; Sonoda, Y.; Levine, D. A.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save